| Application | Recommended Dilution |
|---|---|
| ELISA | 1:10000-1:50000 |
| GICA | 1:500-1:5000 |
The SARS-CoV-2 nucleocapsid protein serves as one of the most abundant viral proteins during infection, playing essential roles in viral RNA packaging, replication, and host cell interactions. Its high immunogenicity and conservation across viral variants have established it as a primary target for COVID-19 diagnostic development and seroprevalence studies, making reliable detection reagents critical for ongoing coronavirus research.
This recombinant monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein offers researchers the consistency and reproducibility that recombinant technology provides. Generated against the full-length nucleoprotein sequence spanning amino acids 1-419, the antibody is produced as a mouse scFv fusion with human IgG1 Fc, combining the specificity of monoclonal selection with a defined molecular format. Because the antibody sequence is fixed and production occurs in controlled expression systems, researchers can expect uniform performance across different lots, eliminating the variability concerns that can complicate longitudinal studies or assay development workflows.
Validation data demonstrate exceptional binding characteristics, with functional ELISA testing revealing an EC50 of 2.928 ng/ml when binding to immobilized SARS-CoV-2 nucleocapsid protein. For rapid detection applications, colloidal gold immunochromatography assay testing shows clean background signal with detection sensitivity reaching as low as 15.625 ng/ml, supporting its utility in point-of-care or high-throughput screening contexts. The recommended working dilutions span 1:10000 to 1:50000 for ELISA and 1:500 to 1:5000 for immunochromatographic applications, offering flexibility to optimize signal-to-noise ratios across different experimental setups.
This antibody supports researchers developing diagnostic platforms, studying viral protein biology, or investigating host-pathogen interactions in the context of SARS-CoV-2 infection.
Email: support@cusabio.com
Distributors Worldwide